Olopatadine
Olopatadine is a potent selective antiallergic/antihistaminic agent. It has multiple distinct mechanisms of action. It antagonises histamine (the primary mediator of allergic response in humans) and prevents histamine induced inflammatory cytokine production by human conjunctival epithelial cells. Data from in vitro studies suggest that it may act on human conjunctival mast cells to inhibit the release of pro-inflammatory mediators. In patients with patent nasolacrimal ducts, topical ocular administration of olopatadine was suggested to reduce the nasal signs and symptoms that frequently accompany seasonal allergic conjunctivitis. It does not produce a clinically significant change in pupil diameter.
Primary Characteristics
Olopatadine is also known as Olopatadine hydrchloride.
It is of Synthetic origin.
It belongs to Anticonjuctivitis , H1-antagonist pharmacological group on the basis of mechanism of action.
Molecular Weight: 373.9 · pKa: 9.4 (piperidinium cation), 5.6 (pyridinium cation) · Solubility in Alcohol: Partically · Non-proprietary name: Olopatadine.
Pharmacokinetics
Absorption: Olopatadine has an oral bioavailability is 21.5% (±21.5%).
Distribution: Olopatadine has a plasma protein binding is 91% in vitro.
Elimination: it is metabolised via hepatic, plasma half-life is 42 hour, renal excretion is 22%, 63% in feces.
Advertisement
Indications
Olopatadine is primarily indicated in conditions like Allergic conjunctivitis.
Contraindications
Olopatadine is contraindicated in conditions like Hypersensitivity to any component of product.
Dosage
Olopatadine's dosage details are as follows:
| Dose | Single Dose | Frequency | Route | Instructions |
|---|---|---|---|---|
| Adult Dosage | ||||
| 2.22 – 0 mg/ml | — | Every 24h | opthalmic | The dose is one drop of olopatadine in the conjunctival sac of the affected eye(s) twice daily (8 hourly). Treatment may be maintained for up to four months, if considered necessary. |
| Paediatric Dosage (20kg) | ||||
| 2.22 – 0 mg/ml | — | Every 24h | opthalmic | The dose is one drop of olopatadine in the conjunctival sac of the affected eye(s) twice daily (8 ho |
| Neonatal Dosage (3kg) | ||||
| 2.22 – 0 mg/ml | — | Every 24h | opthalmic | The dose is one drop of olopatadine in the conjunctival sac of the affected eye(s) twice daily (8 hourly). Treatment may be maintained for up to four months, if considered necessary. |
Drug Interactions
None recorded.
Side Effects
Olopatadine is known to cause more or less tolerable side effects which are usually transient. These include Asthenia , Back pain, Blurred vision, Burning eyes, Cough , Dermatitis, dizziness, Dryness of eye, Dryness of nose, Eye irritation, Eye Pain , Flu like syndrome, Foreign body sensation, Headache, Hyperemia, Increased tearing, Infection, Lids edema, Nausea, Photophobia , Rhinitis , Sinusitis , stingling, Tiredness , Weakness.
Warnings / Precautions
Available Brands
Click on a strength to view available brands.
Single Ingredient
Storage Conditions
Drug Classification
- 1.21.6 — Non-specific anticonjunctivitis preparations